⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 2, 2024

Supplementary Figure 8 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD⁺ Depletion

Katelyn J. Noronha Karlie N. Lucas Sateja Paradkar Joseph Edmonds Sam Friedman Matthew A. Murray Samantha Liu Dipti P. Sajed Chana Sachs Josh Spurrier Mitch Raponi Jiayu Liang Hao Zeng Ranjini K. Sundaram Brian Shuch Juan C. Vasquez Ranjit S. Bindra

View at Publisher

Ask AI

Bookmark

Share

Abstract

NAPRT silencing confers sensitivity to NAMPTis in IDH1/2 mutant cancer cell line models.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Noronha et al. (2024) studied this question.

synapsesocial.com/papers/68e56004e2b3180350efd120 https://doi.org/10.1158/1541-7786.27151063

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 4 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024
2Supplementary Figure 7 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024
3Supplementary Figure 6 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024
4Supplementary Figure 3 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024
5Supplementary Figure 2 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024

Supplementary Figure 11 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024
Supplementary Figure 5 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024
Supplementary Figure 12 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024